Background: Aberrations in Capicua (CIC) have lately been implicated as a adverse prognostic consider a mess of most cancers sorts by means of the derepression of targets downstream of the mitogen-activated protein kinase (MAPK) signaling cascade, similar to oncogenic E26 transformation-specific (ETS) transcription components. The Ataxin-family protein ATXN1L has beforehand been reported to work together with CIC in each developmental and illness contexts to facilitate the repression of CIC goal genes and promote the post-translational stability of CIC. Nevertheless, little is understood concerning the mechanisms on the base of ATXN1L-mediated CIC post-translational stability.

Outcomes: Useful in vitro research using ATXN1L human cell traces revealed that lack of ATXN1L results in the buildup of polyubiquitinated CIC protein, selling its degradation by means of the proteasome. Though transcriptomic signatures of ATXN1L^KO cell traces indicated upregulation of the mitogen-activated protein kinase pathway, ERK exercise was discovered to contribute to CIC operate however not stability. Degradation of CIC protein following lack of ATXN1L was as an alternative noticed to be mediated by the E3 ubiquitin ligase TRIM25 which was additional validated utilizing glioma-derived cell traces and the TCGA breast carcinoma and liver hepatocellular carcinoma cohorts.

Conclusions: The post-translational regulation of CIC by means of ATXN1L and TRIM25 unbiased of ERK exercise means that the regulation of CIC stability and performance is extra intricate than beforehand appreciated and includes a number of unbiased pathways. As CIC standing has develop into a prognostic consider a number of most cancers sorts, additional data into the mechanisms which govern CIC stability and performance could show helpful for future therapeutic approaches.

Dendrites require exact and well timed supply of protein substrates to distal areas to make sure the proper morphology and performance of neurons. Many of those protein substrates are equipped within the type of ribonucleoprotein (RNP) complicated consisting of RNA-binding proteins (RBPs) and mRNAs, that are subsequently translated in distal dendritic areas. It stays elusive, nonetheless, whether or not key RBPs provide mRNA in line with native calls for individually or in a coordinated method.

On this examine, we investigated how Drosophila sensory neurons reply to the dysregulation of a disease-associated RBP, Ataxin-2 (ATX2), which ends up in dendritic defects. We discovered that ATX2 performs an important function in spacing dendritic branches for the optimum dendritic receptive fields in Drosophila class IV dendritic arborization (C4da) neurons, the place each expression degree and subcellular location of ATX2 contribute considerably to this impact. We confirmed that translational upregulation by means of the expression of eukaryotic translation initiation issue 4E (eIF4E) additional enhanced the ATX2-induced dendritic phenotypes. Moreover, we discovered that the expression degree of one other disease-associated RBP, fragile X psychological retardation protein (FMRP), decreased in each cell our bodies and dendrites when neurons had been confronted with aberrant upregulation of ATX2. Lastly, we revealed that the PAM2 motif of ATX2, which mediates its interplay with poly(A)-binding protein (PABP), is probably mandatory for the lower of FMRP in sure neuronal stress situations.

Collectively, our knowledge counsel that dysregulation of RBPs triggers a compensatory regulation of different functionally-overlapping RBPs to reduce RBP dysregulation-associated aberrations that hinder neuronal homeostasis in dendrites. Lignin-carbohydrate complicated (LCC) is the organic macromolecule that has been demonstrated to exert a number of organic capabilities, together with antioxidant, anti-inflammation and anti-tumorigenesis, which help its broad utility within the bioengineering discipline. Nevertheless, it stays elusive the involvements of LCC in human neurological issues, particularly these with the overproduction of reactive oxygen species (ROS), similar to spinocerebellar ataxias (SCAs). On this examine, we discovered a beforehand undetermined anti-protein aggregation exercise of LCC.

TAR DNA-binding protein of 43 kDa (TDP-43) is a serious element of intracellular aggregates fashioned in brains of the sufferers with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), that are correctively known as TDP-43 proteinopathies. A hyperlink between Ataxin-2 (ATXN2) and TDP-43 proteinopathies was established when intermediate CAG repeat expansions of ATXN2 gene had been discovered to be related to ALS and it was proven that ATXN2 modifies TDP-43 toxicity. Though ATXN2’s contribution to TDP-43 proteinopathies has been largely studied in ALS, current research have proven that intermediate repeat expansions of ATXN2 additionally affect the phenotype of FTLD by an unknown mechanism. To handle this difficulty, we immunohistochemically and biochemically analyzed the intracellular dynamics of ATXN2 in brains of regular controls and FTLD-TDP circumstances.

The immunohistochemical research revealed that ATXN2 localized within the neuronal cytoplasm and proximal dendrites, and expressed broadly and uniformly in regular human brains. A semi-quantitative immunofluorescent evaluation of regular brains revealed that the cytoplasmic ATXN2 strongly associates with ribosomal protein S6 and poly-A binding protein 1 and partially overlaps with the endoplasmic reticulum marker Calnexin, suggesting a serious function of ATXN2 in protein synthesis. The outcomes of immunohistochemical and biochemical analyses of brains from FTLD-TDP circumstances confirmed the colocalization of ATXN2 and phosphorylated TDP-43 within the dystrophic neurites and the neuronal cytoplasmic inclusions within the hippocampal area, and a major discount of ATXN2 protein in comparison with controls.

Ataxin 1 Antibody
E18-6347-1	EnoGene	50μg/50μl	EUR 145
Description: Available in various conjugation types.

Ataxin 1 Antibody
E18-6347-2	EnoGene	100μg/100μl	EUR 225
Description: Available in various conjugation types.

Ataxin 1 Antibody
E11-0771B	EnoGene	100μg	EUR 225
Description: Available in various conjugation types.

Ataxin 1 Antibody
MBS9601916-01mL	MyBiosource	0.1mL	EUR 260

Ataxin 1 Antibody
MBS9601916-02mL	MyBiosource	0.2mL	EUR 305

Ataxin 1 Antibody
MBS9601916-5x02mL	MyBiosource	5x0.2mL	EUR 1220

Ataxin 1 Antibody
MBS8509598-01mg	MyBiosource	0.1mg	EUR 305

Ataxin 1 Antibody
MBS8509598-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 465

Ataxin 1 Antibody
MBS8509598-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 465

Ataxin 1 Antibody
MBS8509598-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 465

Ataxin 1 Antibody
MBS8509598-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 465

Ataxin 1 Antibody
MBS8512374-005mg	MyBiosource	0.05mg	EUR 235

Ataxin 1 Antibody
MBS8512374-01mg	MyBiosource	0.1mg	EUR 305

Ataxin 1 Antibody
MBS8512374-01mLAF405M	MyBiosource	0.1mL(AF405M)	EUR 465

Ataxin 1 Antibody
MBS8512374-01mLAF546	MyBiosource	0.1mL(AF546)	EUR 465

Ataxin 1 Antibody
MBS8512374-01mLAF750	MyBiosource	0.1mL(AF750)	EUR 465

Ataxin 1 Antibody
MBS9503754-005mL	MyBiosource	0.05mL	EUR 285

Ataxin 1 Antibody
MBS9503754-01mL	MyBiosource	0.1mL	EUR 385

Ataxin 1 Antibody
MBS9503754-5x01mL	MyBiosource	5x0.1mL	EUR 1590

Ataxin 1 Antibody
MBS801582-01mg	MyBiosource	0.1mg	EUR 435

Ataxin 1 Antibody
MBS801582-5x01mg	MyBiosource	5x0.1mg	EUR 1700

Ataxin 1 Antibody
MBS804474-01mg	MyBiosource	0.1mg	EUR 435

Ataxin 1 Antibody
MBS804474-5x01mg	MyBiosource	5x0.1mg	EUR 1700

Ataxin 1 Antibody
SMC-455D	Stressmarq	0.1mg	EUR 231
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody
SMC-455S	Stressmarq	0.012mg	Ask for price
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody
SMC-475D	Stressmarq	0.1mg	EUR 231
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody
SMC-475S	Stressmarq	0.012mg	Ask for price
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin-1 Antibody
B0771-100ul	Assay Biotech	100μl	EUR 217
Description: Ataxin-1 Rabbit Polyclonal Antibody

Ataxin-1 Antibody
B0771-50ul	Assay Biotech	50μl	EUR 143.5
Description: Ataxin-1 Rabbit Polyclonal Antibody

Ataxin-1 Antibody
E90506	EnoGene	100μg	EUR 255
Description: Available in various conjugation types.

Ataxin-1 Antibody
MBS8503880-01mg	MyBiosource	0.1mg	EUR 325

Ataxin-1 Antibody
MBS8503880-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 565

Ataxin-1 Antibody
MBS8503880-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 565

Ataxin-1 Antibody
MBS8503880-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 565

Ataxin-1 Antibody
MBS8503880-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 565

Ataxin 1 Antibody: HRP
MBS801879-01mg	MyBiosource	0.1mg	EUR 475

Ataxin 1 Antibody: HRP
MBS801879-5x01mg	MyBiosource	5x0.1mg	EUR 1885

Ataxin 1 Antibody: RPE
MBS802293-01mg	MyBiosource	0.1mg	EUR 485

Ataxin 1 Antibody: RPE
MBS802293-5x01mg	MyBiosource	5x0.1mg	EUR 1925

Ataxin 1 Antibody: RPE
MBS802630-01mg	MyBiosource	0.1mg	EUR 485

Ataxin 1 Antibody: RPE
MBS802630-5x01mg	MyBiosource	5x0.1mg	EUR 1925

Ataxin 1 Antibody: HRP
MBS803533-01mg	MyBiosource	0.1mg	EUR 475

Ataxin 1 Antibody: HRP
MBS803533-5x01mg	MyBiosource	5x0.1mg	EUR 1885

Ataxin 1 Antibody: APC
SMC-455D-APC	Stressmarq	0.1mg	EUR 267.4
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: HRP
SMC-455D-HRP	Stressmarq	0.1mg	EUR 259
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: RPE
SMC-455D-RPE	Stressmarq	0.1mg	EUR 266
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: APC
SMC-475D-APC	Stressmarq	0.1mg	EUR 267.4
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: HRP
SMC-475D-HRP	Stressmarq	0.1mg	EUR 259
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: RPE
SMC-475D-RPE	Stressmarq	0.1mg	EUR 266
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: FITC
MBS801486-01mg	MyBiosource	0.1mg	EUR 480

Ataxin 1 Antibody: FITC
MBS801486-5x01mg	MyBiosource	5x0.1mg	EUR 1905

Ataxin 1 Antibody: FITC
MBS804612-01mg	MyBiosource	0.1mg	EUR 480

Ataxin 1 Antibody: FITC
MBS804612-5x01mg	MyBiosource	5x0.1mg	EUR 1905

Ataxin 1 Antibody: FITC
SMC-455D-FITC	Stressmarq	0.1mg	EUR 261.8
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: FITC
SMC-475D-FITC	Stressmarq	0.1mg	EUR 261.8
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: PerCP
MBS800951-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: PerCP
MBS800951-5x01mg	MyBiosource	5x0.1mg	EUR 1935

Ataxin 1 Antibody: PerCP
MBS803830-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: PerCP
MBS803830-5x01mg	MyBiosource	5x0.1mg	EUR 1935

Ataxin 1 Antibody: PerCP
SMC-455D-PCP	Stressmarq	0.1mg	EUR 267.4
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: PerCP
SMC-475D-PCP	Stressmarq	0.1mg	EUR 267.4
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: Biotin
MBS802698-01mg	MyBiosource	0.1mg	EUR 485

Ataxin 1 Antibody: Biotin
MBS802698-5x01mg	MyBiosource	5x0.1mg	EUR 1920

Ataxin 1 Antibody: Biotin
MBS804344-01mg	MyBiosource	0.1mg	EUR 485

Ataxin 1 Antibody: Biotin
MBS804344-5x01mg	MyBiosource	5x0.1mg	EUR 1920

Ataxin 1 Antibody: Biotin
SMC-455D-BI	Stressmarq	0.1mg	EUR 264.6
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: Biotin
SMC-475D-BI	Stressmarq	0.1mg	EUR 264.6
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: ATTO 488
MBS800855-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: ATTO 488
MBS800855-5x01mg	MyBiosource	5x0.1mg	EUR 1940

Ataxin 1 Antibody: ATTO 488
MBS802787-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: ATTO 488
MBS802787-5x01mg	MyBiosource	5x0.1mg	EUR 1940

Ataxin 1 Antibody: ATTO 390
MBS803174-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: ATTO 390
MBS803174-5x01mg	MyBiosource	5x0.1mg	EUR 1945

Ataxin 1 Antibody: ATTO 390
MBS803372-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: ATTO 390
MBS803372-5x01mg	MyBiosource	5x0.1mg	EUR 1945

Ataxin 1 Antibody: ATTO 594
MBS804824-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: ATTO 594
MBS804824-5x01mg	MyBiosource	5x0.1mg	EUR 1940

Ataxin 1 Antibody: ATTO 594
MBS804868-01mg	MyBiosource	0.1mg	EUR 490

Ataxin 1 Antibody: ATTO 594
MBS804868-5x01mg	MyBiosource	5x0.1mg	EUR 1940

Ataxin 1 Antibody: ATTO 390
SMC-455D-A390	Stressmarq	0.1mg	EUR 268.8
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: ATTO 488
SMC-455D-A488	Stressmarq	0.1mg	EUR 268.1
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: ATTO 594
SMC-455D-A594	Stressmarq	0.1mg	EUR 268.1
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG2b

Ataxin 1 Antibody: ATTO 390
SMC-475D-A390	Stressmarq	0.1mg	EUR 268.8
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: ATTO 488
SMC-475D-A488	Stressmarq	0.1mg	EUR 268.1
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 Antibody: ATTO 594
SMC-475D-A594	Stressmarq	0.1mg	EUR 268.1
Description: Mouse Anti-Mouse Ataxin 1 Monoclonal IgG1

Ataxin 1 (ATXN1) Polyclonal Antibody (Human, Mouse, Rat)
4-PAA514Hu01	Cloud-Clone	Ask for price Ask for price Ask for price Ask for price Ask for price	20ul 100ul 200ul 1ml 10ml
Description: A Rabbit polyclonal antibody against Human, Mouse, Rat Ataxin 1 (ATXN1)

Ataxin-1 Polyclonal Antibody
40621-100ul	SAB	100ul	EUR 302.4

Ataxin-1 Polyclonal Antibody
40621-50ul	SAB	50ul	EUR 224.4

Ataxin-1 Polyclonal Antibody
ABP50719-003ml	Abbkine	0.03ml	EUR 189.6
Description: A polyclonal antibody for detection of Ataxin-1 from Human, Mouse. This Ataxin-1 antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ataxin-1 around the non-phosphorylation site of S776

Ataxin-1 Polyclonal Antibody
ABP50719-01ml	Abbkine	0.1ml	EUR 346.8
Description: A polyclonal antibody for detection of Ataxin-1 from Human, Mouse. This Ataxin-1 antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ataxin-1 around the non-phosphorylation site of S776

Ataxin-1 Polyclonal Antibody
ABP50719-02ml	Abbkine	0.2ml	EUR 496.8
Description: A polyclonal antibody for detection of Ataxin-1 from Human, Mouse. This Ataxin-1 antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ataxin-1 around the non-phosphorylation site of S776

Ataxin-1 Monoclonal Antibody
BT-MCA0188-100ul	Jiaxing Korain Biotech Ltd (BT Labs)	100ul	Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted

Ataxin-1 Monoclonal Antibody
BT-MCA0188-50ul	Jiaxing Korain Biotech Ltd (BT Labs)	50ul	Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted

Ataxin-1 Polyclonal Antibody
BT-AP00685-100ul	Jiaxing Korain Biotech Ltd (BT Labs)	100ul	Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

Ataxin-1 Polyclonal Antibody
BT-AP00685-20ul	Jiaxing Korain Biotech Ltd (BT Labs)	20ul	Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

Ataxin-1 Polyclonal Antibody
BT-AP00685-50ul	Jiaxing Korain Biotech Ltd (BT Labs)	50ul	Ask for price
Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1.

Ataxin-1 polyclonal antibody
BS7968	Bioworld Biotech	50ul	EUR 358
Description: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Ataxin-1 Polyclonal Antibody
E040621	EnoGene	100μg/100μl	EUR 255
Description: Available in various conjugation types.

Ataxin-1 Polyclonal Antibody
E20-70373	EnoGene	100ug	EUR 225
Description: Available in various conjugation types.

Ataxin-1 Polyclonal Antibody
E44H01617	EnoGene	100ul	EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Ataxin-1 Polyclonal Antibody
JOT-AP00685-100ul	Jotbody	100ul	EUR 220
Description: Human;Mouse

Ataxin-1 Polyclonal Antibody
JOT-AP00685-50ul	Jotbody	50ul	EUR 144
Description: Human;Mouse

Ataxin-1 Monoclonal Antibody
JOT-MCA0188-100ul	Jotbody	100ul	EUR 220

Ataxin-1 Monoclonal Antibody
JOT-MCA0188-50ul	Jotbody	50ul	EUR 144

Ataxin-1 Monoclonal Antibody
MBS191333-01mg	MyBiosource	0.1mg	EUR 650

Ataxin-1 Monoclonal Antibody
MBS191333-5x01mg	MyBiosource	5x0.1mg	EUR 2925

Ataxin-1 Monoclonal Antibody
MBS191334-01mg	MyBiosource	0.1mg	EUR 650

Ataxin-1 Monoclonal Antibody
MBS191334-5x01mg	MyBiosource	5x0.1mg	EUR 2925

Ataxin-1 Polyclonal Antibody
MBS2537932-002mL	MyBiosource	0.02mL	EUR 140

Ataxin-1 Polyclonal Antibody
MBS2537932-006mL	MyBiosource	0.06mL	EUR 180

Ataxin-1 Polyclonal Antibody
MBS2537932-012mL	MyBiosource	0.12mL	EUR 260

Ataxin-1 Polyclonal Antibody
MBS2537932-02mL	MyBiosource	0.2mL	EUR 405

Ataxin-1 Polyclonal Antibody
MBS8521354-01mg	MyBiosource	0.1mg	EUR 305

Ataxin-1 Polyclonal Antibody
MBS8521354-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 465

Ataxin-1 Polyclonal Antibody
MBS8521354-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 465

Ataxin-1 Polyclonal Antibody
MBS8521354-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 465

Ataxin-1 Polyclonal Antibody
MBS8521354-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 465

Ataxin-1 Polyclonal Antibody
MBS9404076-005mL	MyBiosource	0.05mL	EUR 245

Ataxin-1 Polyclonal Antibody
MBS9404076-01mL	MyBiosource	0.1mL	EUR 305

Ataxin-1 Polyclonal Antibody
MBS9404076-5x01mL	MyBiosource	5x0.1mL	EUR 1230

Ataxin-1 Monoclonal Antibody
UB-GEN-3311	UpingBio	100 ul	EUR 200

Ataxin-1 Polyclonal Antibody
UB-GEN-3648	UpingBio	100 ul	EUR 200

Human Ataxin 1 (ATXN1) Antibody Pair Kit (with Standard)
MBS2099035-10x96Tests	MyBiosource	10x96Tests	EUR 1480

Human Ataxin 1 (ATXN1) Antibody Pair Kit (with Standard)
MBS2099035-10x96TestsMBS2090685AbPairsSupportPack110x96Tests	MyBiosource	10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)	EUR 1600

Human Ataxin 1 (ATXN1) Antibody Pair Kit (with Standard)
MBS2099035-5x96Tests	MyBiosource	5x96Tests	EUR 935

Human Ataxin 1 (ATXN1) Antibody Pair Kit (with Standard)
MBS2099035-5x96TestsMBS2090685AbPairsSupportPack15x96Tests	MyBiosource	5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)	EUR 1010

Ataxin 1 (ATXN1) Antibody
abx320078-100l	Abbexa	100 µl	EUR 350

Ataxin 1 (ATXN1) Antibody
20-abx320078	Abbexa	Ask for price Ask for price	50 ul 100 ul

Ataxin 1 (ATXN1) Antibody
abx320078-50l	Abbexa	50 µl	EUR 237.5

Ataxin 1 (ATXN1) Antibody
20-abx171342	Abbexa	Ask for price Ask for price	200 ug 1 mg

Ataxin 1 (ATXN1) Antibody
abx171342-1ml	Abbexa	1 ml	EUR 712.5

Ataxin 1 (ATXN1) Antibody
abx325351-100g	Abbexa	100 µg	EUR 250

Ataxin 1 (ATXN1) Antibody
20-abx325351	Abbexa	Ask for price Ask for price	50 ug 100 ug

Ataxin 1 (ATXN1) Antibody
abx325351-50g	Abbexa	50 µg	EUR 187.5

Ataxin 1 (ATXN1) Antibody
abx431572-200l	Abbexa	200 µl	EUR 250

Ataxin 1 (ATXN1) Antibody
abx431572-200ul	Abbexa	200 ul	EUR 343.2

Ataxin 1 (ATXN1) Antibody
abx432383-100g	Abbexa	100 µg	EUR 250

Ataxin 1 (ATXN1) Antibody
abx432383-200ul	Abbexa	200 ul	EUR 343.2

Ataxin 1 (ATXN1) Antibody
abx445066-100g	Abbexa	100 µg	EUR 550

Ataxin 1 (ATXN1) Antibody
abx445066-100ug	Abbexa	100 ug	EUR 627.6

Ataxin 1 (ATXN1) Antibody
abx445084-100g	Abbexa	100 µg	EUR 550

Ataxin 1 (ATXN1) Antibody
abx445084-100ug	Abbexa	100 ug	EUR 627.6

Ataxin 1 (ATXN1) Antibody
abx100304-100l	Abbexa	100 µl	EUR 250

These outcomes counsel that ATXN2 is concerned within the pathological strategy of FTLD-TDP. It stays to be clarified whether or not decreased ATXN2 expression induces neurodegeneration by impairing protein synthesis or performs a neuroprotective function by attenuating the toxicity of TDP-43 aggregates in FTLD-TDP and different TDP-43 proteinopathies.